Validity of the Spanish Version of Subjective Well-being Under Neuroleptics Scale (SWN-K) in Patients With Schizophrenia

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00749970
First received: September 9, 2008
Last updated: December 8, 2010
Last verified: December 2010

September 9, 2008
December 8, 2010
July 2008
January 2009   (final data collection date for primary outcome measure)
  • SWN-K [ Time Frame: 7 days ] [ Designated as safety issue: No ]
  • PANSS [ Time Frame: 7 days ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00749970 on ClinicalTrials.gov Archive Site
CGI-I [ Time Frame: 7 days ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Validity of the Spanish Version of Subjective Well-being Under Neuroleptics Scale (SWN-K) in Patients With Schizophrenia
Validity of the Spanish Version of Subjective Well-being Under Neuroleptics Scale (SWN-K) in Patients With Schizophrenia

Observational, short-term prospective, multicenter study to assess psychometric properties of the Spanish version of SWN-K scale in patients with schizophrenia.

Not Provided
Observational
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Patient aged 18-year old or older with a diagnosis of schizophrenia, schizoaffective disorder, or shizophreniform disorder

  • Schizophrenia
  • Schizoaffective Disorder
  • Schizophreniform Disorder
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
100
January 2009
January 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with a diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform disorder (DSM-IV TR criteria)
  • Stabilized out-patients
  • Under treatment with an oral antipsychotic drug

Exclusion Criteria:

  • Administration of a depot antipsychotic drug
  • Participation in another clinical trial within 4 weeks prior to enrolment into this study
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Spain
 
NCT00749970
NIS-NES-DUM-2008/1
No
Teresa Diez, AstraZeneca Pharmaceuticals
AstraZeneca
Not Provided
Not Provided
AstraZeneca
December 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP